| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cell Transplantation | 108 | 2023 | 6550 | 5.530 |
Why?
|
| Graft vs Host Disease | 39 | 2022 | 2638 | 2.780 |
Why?
|
| Transplantation Conditioning | 46 | 2022 | 2238 | 2.580 |
Why?
|
| Transplantation, Homologous | 43 | 2023 | 2843 | 1.840 |
Why?
|
| Multiple Myeloma | 23 | 2022 | 2138 | 1.730 |
Why?
|
| Transplantation, Autologous | 28 | 2022 | 1914 | 1.630 |
Why?
|
| Bone Marrow Transplantation | 12 | 2020 | 1581 | 1.320 |
Why?
|
| Unrelated Donors | 15 | 2022 | 304 | 1.140 |
Why?
|
| Amyloidosis | 5 | 2020 | 176 | 0.970 |
Why?
|
| Myelodysplastic Syndromes | 14 | 2022 | 2979 | 0.870 |
Why?
|
| Myeloablative Agonists | 10 | 2020 | 384 | 0.860 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 12 | 2022 | 2796 | 0.840 |
Why?
|
| Leukemia, Myeloid, Acute | 19 | 2021 | 6915 | 0.840 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 6 | 2020 | 749 | 0.790 |
Why?
|
| Roseolovirus Infections | 3 | 2011 | 39 | 0.690 |
Why?
|
| Herpesvirus 6, Human | 3 | 2011 | 81 | 0.670 |
Why?
|
| Leukemia | 7 | 2022 | 1635 | 0.660 |
Why?
|
| Photosensitivity Disorders | 1 | 2018 | 23 | 0.660 |
Why?
|
| Adult | 97 | 2022 | 77950 | 0.660 |
Why?
|
| Voriconazole | 1 | 2018 | 108 | 0.630 |
Why?
|
| Siblings | 12 | 2022 | 285 | 0.620 |
Why?
|
| Middle Aged | 90 | 2022 | 86204 | 0.610 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2019 | 366 | 0.600 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 6 | 2019 | 216 | 0.590 |
Why?
|
| Male | 102 | 2022 | 123000 | 0.570 |
Why?
|
| Humans | 156 | 2023 | 261506 | 0.570 |
Why?
|
| Allografts | 17 | 2021 | 650 | 0.560 |
Why?
|
| Tissue Donors | 11 | 2021 | 769 | 0.560 |
Why?
|
| Iron Overload | 2 | 2006 | 35 | 0.560 |
Why?
|
| Immunosuppressive Agents | 6 | 2020 | 1375 | 0.560 |
Why?
|
| Hematologic Neoplasms | 9 | 2021 | 1870 | 0.530 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2019 | 489 | 0.500 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 5 | 2020 | 266 | 0.500 |
Why?
|
| Lymphoma, Follicular | 4 | 2017 | 587 | 0.490 |
Why?
|
| Heart Transplantation | 3 | 2020 | 908 | 0.480 |
Why?
|
| Aged | 63 | 2022 | 70117 | 0.480 |
Why?
|
| Skin Ulcer | 1 | 2014 | 77 | 0.480 |
Why?
|
| Female | 94 | 2022 | 141928 | 0.470 |
Why?
|
| Encephalitis, Varicella Zoster | 1 | 2013 | 2 | 0.470 |
Why?
|
| Leukemoid Reaction | 1 | 2013 | 12 | 0.460 |
Why?
|
| Meningoencephalitis | 1 | 2013 | 24 | 0.460 |
Why?
|
| Neoplasms, Second Primary | 8 | 2017 | 1350 | 0.460 |
Why?
|
| Adolescent | 47 | 2022 | 31252 | 0.450 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 6 | 2020 | 1664 | 0.440 |
Why?
|
| Disease-Free Survival | 28 | 2022 | 10001 | 0.430 |
Why?
|
| Anemia, Aplastic | 3 | 2020 | 214 | 0.420 |
Why?
|
| T-Lymphocytes | 8 | 2021 | 3869 | 0.420 |
Why?
|
| Melphalan | 8 | 2022 | 834 | 0.420 |
Why?
|
| Azoles | 1 | 2012 | 47 | 0.410 |
Why?
|
| Budesonide | 1 | 2012 | 34 | 0.410 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 5 | 2016 | 2390 | 0.410 |
Why?
|
| Gout | 1 | 2011 | 31 | 0.400 |
Why?
|
| Stem Cell Transplantation | 5 | 2022 | 1360 | 0.400 |
Why?
|
| Cushing Syndrome | 1 | 2012 | 70 | 0.400 |
Why?
|
| Young Adult | 38 | 2022 | 21445 | 0.400 |
Why?
|
| Recurrence | 20 | 2022 | 4758 | 0.400 |
Why?
|
| Cyclosporine | 2 | 2019 | 278 | 0.400 |
Why?
|
| Cardiomyopathies | 2 | 2019 | 610 | 0.390 |
Why?
|
| Lymphoma | 5 | 2021 | 1467 | 0.380 |
Why?
|
| Treatment Outcome | 41 | 2021 | 32848 | 0.380 |
Why?
|
| Thalidomide | 1 | 2014 | 569 | 0.380 |
Why?
|
| Lymphoma, Non-Hodgkin | 5 | 2020 | 1039 | 0.370 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 3719 | 0.360 |
Why?
|
| Salvage Therapy | 6 | 2021 | 2054 | 0.360 |
Why?
|
| Graft vs Leukemia Effect | 2 | 2021 | 105 | 0.350 |
Why?
|
| HLA Antigens | 7 | 2019 | 546 | 0.350 |
Why?
|
| Antibodies, Monoclonal | 4 | 2020 | 4367 | 0.350 |
Why?
|
| Leukemia, Myeloid | 4 | 2017 | 941 | 0.340 |
Why?
|
| Incidence | 8 | 2019 | 5673 | 0.330 |
Why?
|
| Survival Analysis | 21 | 2021 | 9180 | 0.330 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2012 | 461 | 0.320 |
Why?
|
| Bone Marrow Cells | 3 | 2021 | 943 | 0.320 |
Why?
|
| Mycophenolic Acid | 2 | 2019 | 148 | 0.320 |
Why?
|
| Child, Preschool | 21 | 2021 | 16273 | 0.310 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 15 | 2022 | 15862 | 0.300 |
Why?
|
| Plasma Cells | 2 | 2020 | 192 | 0.300 |
Why?
|
| Eye Diseases | 2 | 2019 | 132 | 0.300 |
Why?
|
| Graft Survival | 4 | 2012 | 1062 | 0.300 |
Why?
|
| Graft Rejection | 2 | 2017 | 834 | 0.300 |
Why?
|
| Metapneumovirus | 1 | 2007 | 58 | 0.300 |
Why?
|
| Encephalitis, Viral | 1 | 2007 | 30 | 0.290 |
Why?
|
| Paramyxoviridae Infections | 1 | 2007 | 86 | 0.290 |
Why?
|
| Paresis | 1 | 2006 | 54 | 0.290 |
Why?
|
| Retrospective Studies | 28 | 2023 | 37905 | 0.290 |
Why?
|
| Hemoglobin SC Disease | 1 | 2006 | 13 | 0.290 |
Why?
|
| Erythrocyte Indices | 1 | 2006 | 24 | 0.280 |
Why?
|
| Child | 29 | 2022 | 29154 | 0.280 |
Why?
|
| Primary Myelofibrosis | 3 | 2023 | 831 | 0.280 |
Why?
|
| Antibodies, Neoplasm | 1 | 2007 | 259 | 0.280 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 4 | 2020 | 2527 | 0.270 |
Why?
|
| Rituximab | 6 | 2022 | 1528 | 0.270 |
Why?
|
| Antigens, CD19 | 4 | 2018 | 577 | 0.270 |
Why?
|
| Infant | 17 | 2021 | 13310 | 0.260 |
Why?
|
| Bone Marrow | 3 | 2021 | 2358 | 0.260 |
Why?
|
| beta 2-Microglobulin | 1 | 2005 | 184 | 0.260 |
Why?
|
| Histocompatibility Testing | 5 | 2021 | 447 | 0.250 |
Why?
|
| Cytokines | 2 | 2011 | 2809 | 0.250 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2005 | 299 | 0.240 |
Why?
|
| Survival Rate | 17 | 2021 | 12221 | 0.240 |
Why?
|
| Erythrocyte Transfusion | 1 | 2006 | 212 | 0.240 |
Why?
|
| Vancomycin | 1 | 2006 | 273 | 0.240 |
Why?
|
| Burkitt Lymphoma | 1 | 2006 | 335 | 0.240 |
Why?
|
| Whole-Body Irradiation | 5 | 2020 | 307 | 0.240 |
Why?
|
| Hodgkin Disease | 3 | 2022 | 1429 | 0.230 |
Why?
|
| Pleural Effusion, Malignant | 1 | 2005 | 156 | 0.230 |
Why?
|
| Maintenance Chemotherapy | 2 | 2022 | 202 | 0.230 |
Why?
|
| Lymphoma, T-Cell | 1 | 2006 | 361 | 0.230 |
Why?
|
| Lymphocyte Transfusion | 2 | 2021 | 175 | 0.230 |
Why?
|
| Acute Disease | 8 | 2019 | 2422 | 0.230 |
Why?
|
| Receptors, Antigen, T-Cell | 3 | 2020 | 1146 | 0.220 |
Why?
|
| Metabolic Syndrome | 2 | 2016 | 353 | 0.220 |
Why?
|
| Janus Kinase Inhibitors | 1 | 2023 | 63 | 0.220 |
Why?
|
| Survivors | 4 | 2019 | 1031 | 0.210 |
Why?
|
| C-Reactive Protein | 1 | 2005 | 527 | 0.210 |
Why?
|
| Leukemia, Prolymphocytic, T-Cell | 1 | 2022 | 43 | 0.200 |
Why?
|
| Cord Blood Stem Cell Transplantation | 2 | 2017 | 362 | 0.200 |
Why?
|
| Cytomegalovirus Infections | 2 | 2023 | 462 | 0.200 |
Why?
|
| Prognosis | 19 | 2021 | 21713 | 0.200 |
Why?
|
| Neutropenia | 1 | 2006 | 968 | 0.200 |
Why?
|
| Quality of Life | 5 | 2023 | 4532 | 0.200 |
Why?
|
| Bacterial Infections | 1 | 2005 | 479 | 0.200 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2020 | 1242 | 0.200 |
Why?
|
| Community Health Planning | 1 | 2020 | 23 | 0.190 |
Why?
|
| Cell- and Tissue-Based Therapy | 2 | 2021 | 406 | 0.190 |
Why?
|
| Liver Diseases | 1 | 2006 | 574 | 0.190 |
Why?
|
| Seizures | 1 | 2006 | 989 | 0.190 |
Why?
|
| Cyclophosphamide | 6 | 2022 | 3001 | 0.190 |
Why?
|
| Peripheral Blood Stem Cells | 1 | 2020 | 9 | 0.190 |
Why?
|
| Busulfan | 4 | 2020 | 764 | 0.180 |
Why?
|
| Blood Transfusion, Autologous | 1 | 2020 | 68 | 0.180 |
Why?
|
| Antigens, Neoplasm | 3 | 2021 | 1506 | 0.180 |
Why?
|
| Health Information Systems | 1 | 2020 | 34 | 0.180 |
Why?
|
| Remission Induction | 9 | 2021 | 3569 | 0.180 |
Why?
|
| Social Determinants of Health | 1 | 2021 | 97 | 0.180 |
Why?
|
| Virus Integration | 2 | 2011 | 76 | 0.180 |
Why?
|
| Time-to-Treatment | 2 | 2019 | 292 | 0.180 |
Why?
|
| Body Mass Index | 5 | 2020 | 2203 | 0.170 |
Why?
|
| Antineoplastic Agents | 3 | 2022 | 14289 | 0.170 |
Why?
|
| United States Food and Drug Administration | 1 | 2020 | 332 | 0.170 |
Why?
|
| Chronic Disease | 7 | 2021 | 1819 | 0.160 |
Why?
|
| Combined Modality Therapy | 9 | 2021 | 8865 | 0.160 |
Why?
|
| Foot Diseases | 1 | 1998 | 52 | 0.160 |
Why?
|
| Tissue and Organ Harvesting | 2 | 2020 | 148 | 0.160 |
Why?
|
| Calcineurin Inhibitors | 1 | 2018 | 68 | 0.160 |
Why?
|
| Minority Groups | 1 | 2020 | 322 | 0.160 |
Why?
|
| Diagnosis, Differential | 3 | 2006 | 4744 | 0.150 |
Why?
|
| United States | 9 | 2021 | 15433 | 0.150 |
Why?
|
| Viral Load | 1 | 2019 | 493 | 0.150 |
Why?
|
| Poverty | 1 | 2021 | 471 | 0.150 |
Why?
|
| Donor Selection | 1 | 2018 | 110 | 0.150 |
Why?
|
| Leukemic Infiltration | 1 | 1997 | 72 | 0.150 |
Why?
|
| Herpesvirus 4, Human | 2 | 2019 | 966 | 0.150 |
Why?
|
| Risk Factors | 13 | 2020 | 17523 | 0.150 |
Why?
|
| Osteonecrosis | 2 | 2014 | 53 | 0.150 |
Why?
|
| Tacrolimus | 1 | 2018 | 335 | 0.150 |
Why?
|
| Registries | 3 | 2020 | 2170 | 0.150 |
Why?
|
| Follow-Up Studies | 10 | 2021 | 14889 | 0.140 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2016 | 73 | 0.140 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2018 | 181 | 0.140 |
Why?
|
| Disease Progression | 8 | 2022 | 6682 | 0.140 |
Why?
|
| Hospitals, Special | 1 | 2015 | 24 | 0.140 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2019 | 328 | 0.140 |
Why?
|
| Activities of Daily Living | 1 | 2019 | 552 | 0.140 |
Why?
|
| Antigens, CD34 | 3 | 2020 | 593 | 0.140 |
Why?
|
| Filgrastim | 3 | 2015 | 191 | 0.130 |
Why?
|
| Ferritins | 2 | 2006 | 151 | 0.130 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2015 | 1303 | 0.130 |
Why?
|
| Cervix Uteri | 1 | 1997 | 253 | 0.130 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2015 | 109 | 0.130 |
Why?
|
| Hospitals, Low-Volume | 1 | 2015 | 53 | 0.130 |
Why?
|
| Methotrexate | 1 | 2018 | 999 | 0.130 |
Why?
|
| Cohort Studies | 9 | 2022 | 9244 | 0.130 |
Why?
|
| Janus Kinase 1 | 1 | 2015 | 121 | 0.130 |
Why?
|
| Testicular Neoplasms | 1 | 2019 | 529 | 0.130 |
Why?
|
| DNA, Viral | 2 | 2007 | 694 | 0.130 |
Why?
|
| Hospitals, High-Volume | 1 | 2015 | 77 | 0.130 |
Why?
|
| Recombinant Proteins | 4 | 2014 | 2927 | 0.120 |
Why?
|
| Caspase 9 | 1 | 2015 | 189 | 0.120 |
Why?
|
| Blood Donors | 3 | 2020 | 164 | 0.120 |
Why?
|
| Sarcoma, Myeloid | 1 | 2015 | 95 | 0.120 |
Why?
|
| Multivariate Analysis | 6 | 2020 | 4298 | 0.120 |
Why?
|
| Translocation, Genetic | 1 | 2020 | 1245 | 0.120 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2019 | 1033 | 0.120 |
Why?
|
| Anemia, Sickle Cell | 1 | 2017 | 339 | 0.120 |
Why?
|
| Social Class | 1 | 2015 | 310 | 0.120 |
Why?
|
| Databases, Factual | 5 | 2021 | 2218 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 1 | 2006 | 2992 | 0.110 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2016 | 273 | 0.110 |
Why?
|
| Cardiovascular Diseases | 2 | 2016 | 2195 | 0.110 |
Why?
|
| Depressive Disorder | 1 | 2017 | 557 | 0.110 |
Why?
|
| Treatment Failure | 4 | 2020 | 1391 | 0.110 |
Why?
|
| Bortezomib | 3 | 2022 | 543 | 0.110 |
Why?
|
| Antifungal Agents | 1 | 2018 | 834 | 0.110 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2017 | 573 | 0.110 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2017 | 502 | 0.110 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2015 | 588 | 0.100 |
Why?
|
| Colchicine | 1 | 2011 | 52 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 3 | 2014 | 864 | 0.100 |
Why?
|
| Administration, Oral | 2 | 2014 | 1544 | 0.100 |
Why?
|
| Biopsy | 2 | 2012 | 3443 | 0.100 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 1586 | 0.100 |
Why?
|
| Allopurinol | 1 | 2011 | 54 | 0.100 |
Why?
|
| Parathyroid Hormone | 1 | 2012 | 194 | 0.100 |
Why?
|
| Janus Kinase 2 | 1 | 2015 | 679 | 0.100 |
Why?
|
| Guideline Adherence | 1 | 2015 | 636 | 0.100 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2016 | 801 | 0.100 |
Why?
|
| Models, Theoretical | 1 | 2015 | 785 | 0.100 |
Why?
|
| Iatrogenic Disease | 1 | 2012 | 183 | 0.100 |
Why?
|
| Autografts | 3 | 2015 | 165 | 0.100 |
Why?
|
| Hematologic Diseases | 1 | 2012 | 242 | 0.100 |
Why?
|
| Fertility Preservation | 1 | 2013 | 150 | 0.100 |
Why?
|
| Meningeal Neoplasms | 1 | 2015 | 441 | 0.100 |
Why?
|
| Carmustine | 2 | 2022 | 214 | 0.100 |
Why?
|
| Fetal Blood | 2 | 2022 | 482 | 0.090 |
Why?
|
| Proportional Hazards Models | 5 | 2020 | 4988 | 0.090 |
Why?
|
| Mass Screening | 2 | 2018 | 1509 | 0.090 |
Why?
|
| Cause of Death | 3 | 2021 | 752 | 0.090 |
Why?
|
| Chromosomes, Human | 1 | 2011 | 295 | 0.090 |
Why?
|
| CD28 Antigens | 1 | 2011 | 202 | 0.090 |
Why?
|
| Bone and Bones | 1 | 2014 | 619 | 0.090 |
Why?
|
| Drug Interactions | 1 | 2012 | 553 | 0.090 |
Why?
|
| Lung Neoplasms | 3 | 2006 | 11538 | 0.090 |
Why?
|
| Prospective Studies | 5 | 2020 | 12873 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2022 | 10035 | 0.090 |
Why?
|
| Steroids | 1 | 2011 | 356 | 0.090 |
Why?
|
| Time Factors | 6 | 2019 | 12926 | 0.090 |
Why?
|
| Dexamethasone | 2 | 2022 | 1450 | 0.090 |
Why?
|
| Age Factors | 5 | 2017 | 5377 | 0.080 |
Why?
|
| Skin Neoplasms | 2 | 2015 | 4654 | 0.080 |
Why?
|
| Aged, 80 and over | 9 | 2020 | 29902 | 0.080 |
Why?
|
| Oxides | 1 | 2009 | 211 | 0.080 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2018 | 1763 | 0.080 |
Why?
|
| Arsenicals | 1 | 2009 | 201 | 0.080 |
Why?
|
| Etoposide | 3 | 2020 | 870 | 0.080 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2009 | 334 | 0.080 |
Why?
|
| B-Lymphocytes | 1 | 2013 | 1294 | 0.080 |
Why?
|
| Cerebrospinal Fluid Proteins | 1 | 2007 | 26 | 0.080 |
Why?
|
| Boronic Acids | 1 | 2009 | 362 | 0.080 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2020 | 4757 | 0.080 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2013 | 713 | 0.070 |
Why?
|
| Gastrointestinal Diseases | 1 | 2012 | 589 | 0.070 |
Why?
|
| Antiviral Agents | 2 | 2023 | 1230 | 0.070 |
Why?
|
| Karyotyping | 2 | 2006 | 1022 | 0.070 |
Why?
|
| Exchange Transfusion, Whole Blood | 1 | 2006 | 13 | 0.070 |
Why?
|
| Alemtuzumab | 1 | 2007 | 198 | 0.070 |
Why?
|
| Depression | 1 | 2017 | 1715 | 0.070 |
Why?
|
| Epoetin Alfa | 1 | 2006 | 27 | 0.070 |
Why?
|
| Darbepoetin alfa | 1 | 2006 | 26 | 0.070 |
Why?
|
| Hematopoietic System | 1 | 2006 | 26 | 0.070 |
Why?
|
| Transferrin | 1 | 2006 | 78 | 0.070 |
Why?
|
| Heart Failure | 1 | 2020 | 2516 | 0.070 |
Why?
|
| Phlebotomy | 1 | 2006 | 26 | 0.070 |
Why?
|
| Pyrazines | 1 | 2009 | 495 | 0.070 |
Why?
|
| Cytomegalovirus | 2 | 2023 | 482 | 0.070 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2006 | 53 | 0.070 |
Why?
|
| Sex Factors | 3 | 2018 | 2139 | 0.070 |
Why?
|
| Cell Count | 2 | 2019 | 508 | 0.070 |
Why?
|
| Severity of Illness Index | 4 | 2019 | 4320 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2006 | 125 | 0.070 |
Why?
|
| Pituitary Gland, Posterior | 1 | 2005 | 7 | 0.070 |
Why?
|
| Myocardium | 1 | 2012 | 1313 | 0.070 |
Why?
|
| Neoplasms | 3 | 2021 | 15193 | 0.070 |
Why?
|
| Drug Resistance | 2 | 2018 | 587 | 0.070 |
Why?
|
| Neoplasm Staging | 4 | 2018 | 13658 | 0.070 |
Why?
|
| Pancreatic Diseases | 1 | 2006 | 108 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2006 | 272 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2013 | 1209 | 0.060 |
Why?
|
| Ciprofloxacin | 1 | 2005 | 89 | 0.060 |
Why?
|
| Clinical Decision-Making | 2 | 2019 | 524 | 0.060 |
Why?
|
| Erythropoietin | 1 | 2006 | 205 | 0.060 |
Why?
|
| Bone Marrow Diseases | 1 | 2006 | 177 | 0.060 |
Why?
|
| Cytarabine | 2 | 2022 | 1973 | 0.060 |
Why?
|
| Lymphoma, B-Cell | 1 | 2011 | 895 | 0.060 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2005 | 181 | 0.060 |
Why?
|
| Tumor Virus Infections | 1 | 2005 | 224 | 0.060 |
Why?
|
| Vincristine | 2 | 2006 | 1511 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2016 | 6207 | 0.060 |
Why?
|
| Retroviridae | 2 | 2016 | 332 | 0.060 |
Why?
|
| Specimen Handling | 1 | 2005 | 299 | 0.060 |
Why?
|
| Down Syndrome | 1 | 2006 | 226 | 0.060 |
Why?
|
| Chromosome Aberrations | 2 | 2021 | 1960 | 0.060 |
Why?
|
| Pituitary Neoplasms | 1 | 2005 | 203 | 0.060 |
Why?
|
| North America | 1 | 2023 | 314 | 0.060 |
Why?
|
| Skin Diseases | 1 | 2006 | 349 | 0.060 |
Why?
|
| Karnofsky Performance Status | 2 | 2015 | 175 | 0.060 |
Why?
|
| Iron | 1 | 2006 | 376 | 0.050 |
Why?
|
| Blood Transfusion | 1 | 2006 | 583 | 0.050 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2006 | 430 | 0.050 |
Why?
|
| Vidarabine | 2 | 2020 | 1341 | 0.050 |
Why?
|
| International Cooperation | 2 | 2014 | 323 | 0.050 |
Why?
|
| Antigens, CD | 1 | 2007 | 1385 | 0.050 |
Why?
|
| Hematopoiesis | 1 | 2005 | 560 | 0.050 |
Why?
|
| Antilymphocyte Serum | 1 | 2022 | 228 | 0.050 |
Why?
|
| Intention to Treat Analysis | 1 | 2021 | 130 | 0.050 |
Why?
|
| Anti-Infective Agents | 1 | 2005 | 446 | 0.050 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2021 | 107 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 1 | 2005 | 945 | 0.050 |
Why?
|
| Transplant Recipients | 1 | 2023 | 324 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 1 | 2007 | 3203 | 0.050 |
Why?
|
| Marital Status | 1 | 2020 | 98 | 0.050 |
Why?
|
| Antibodies, Viral | 1 | 2007 | 1320 | 0.050 |
Why?
|
| Mutation | 2 | 2020 | 15179 | 0.050 |
Why?
|
| Doxorubicin | 2 | 2006 | 3005 | 0.050 |
Why?
|
| Tumor Burden | 1 | 2006 | 1987 | 0.050 |
Why?
|
| Risk Assessment | 3 | 2017 | 6869 | 0.040 |
Why?
|
| Ifosfamide | 2 | 2018 | 344 | 0.040 |
Why?
|
| Demography | 1 | 2021 | 435 | 0.040 |
Why?
|
| Hepatitis C | 1 | 2005 | 524 | 0.040 |
Why?
|
| Killer Cells, Natural | 1 | 2005 | 904 | 0.040 |
Why?
|
| Infant, Newborn | 3 | 2018 | 8223 | 0.040 |
Why?
|
| CD4-CD8 Ratio | 1 | 2019 | 58 | 0.040 |
Why?
|
| Immunophenotyping | 2 | 2016 | 1681 | 0.040 |
Why?
|
| Cytogenetic Analysis | 1 | 2020 | 568 | 0.040 |
Why?
|
| Obesity | 1 | 2011 | 2884 | 0.040 |
Why?
|
| Insurance Coverage | 1 | 2021 | 256 | 0.040 |
Why?
|
| Longitudinal Studies | 2 | 2014 | 1945 | 0.040 |
Why?
|
| Medicaid | 1 | 2021 | 279 | 0.040 |
Why?
|
| Fatal Outcome | 2 | 1997 | 829 | 0.040 |
Why?
|
| Public Health | 1 | 2020 | 299 | 0.040 |
Why?
|
| Blast Crisis | 1 | 2020 | 557 | 0.040 |
Why?
|
| Retreatment | 1 | 2018 | 452 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2019 | 6100 | 0.040 |
Why?
|
| Pericardial Window Techniques | 1 | 1996 | 6 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2016 | 2232 | 0.040 |
Why?
|
| Feasibility Studies | 2 | 2016 | 2292 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2005 | 4892 | 0.040 |
Why?
|
| Blood Specimen Collection | 1 | 1997 | 93 | 0.030 |
Why?
|
| Liver | 1 | 2006 | 2961 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2017 | 329 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2007 | 3251 | 0.030 |
Why?
|
| Pericardial Effusion | 1 | 1996 | 118 | 0.030 |
Why?
|
| Proteasome Inhibitors | 1 | 2016 | 231 | 0.030 |
Why?
|
| Imatinib Mesylate | 1 | 2019 | 1665 | 0.030 |
Why?
|
| Genes, Transgenic, Suicide | 1 | 2015 | 69 | 0.030 |
Why?
|
| Probability | 1 | 2017 | 866 | 0.030 |
Why?
|
| Mortality | 1 | 2017 | 343 | 0.030 |
Why?
|
| Blood Cell Count | 1 | 2015 | 225 | 0.030 |
Why?
|
| Body Weight | 1 | 2020 | 1293 | 0.030 |
Why?
|
| Karyotype | 1 | 2015 | 234 | 0.030 |
Why?
|
| Organic Chemicals | 1 | 2015 | 113 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2021 | 1656 | 0.030 |
Why?
|
| Carboplatin | 1 | 2018 | 823 | 0.030 |
Why?
|
| Lymphocytes | 1 | 2020 | 1234 | 0.030 |
Why?
|
| Morbidity | 1 | 2016 | 397 | 0.030 |
Why?
|
| Income | 1 | 2015 | 222 | 0.030 |
Why?
|
| Platelet Count | 1 | 2015 | 490 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 2014 | 334 | 0.030 |
Why?
|
| Transplantation, Isogeneic | 1 | 2013 | 56 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2015 | 684 | 0.030 |
Why?
|
| Disease Management | 1 | 2019 | 1052 | 0.030 |
Why?
|
| Adoptive Transfer | 1 | 2016 | 446 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2014 | 249 | 0.030 |
Why?
|
| Ganglioneuroma | 1 | 1993 | 41 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2015 | 699 | 0.030 |
Why?
|
| Protein Engineering | 1 | 2013 | 100 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2018 | 795 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 1489 | 0.030 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2016 | 393 | 0.030 |
Why?
|
| Haplotypes | 1 | 2015 | 856 | 0.030 |
Why?
|
| Immunologic Factors | 1 | 2016 | 649 | 0.030 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 833 | 0.030 |
Why?
|
| Cataract | 1 | 2014 | 218 | 0.030 |
Why?
|
| Spinal Cord Neoplasms | 1 | 1993 | 142 | 0.030 |
Why?
|
| Health Care Costs | 1 | 2017 | 674 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2015 | 703 | 0.030 |
Why?
|
| Anesthesia | 1 | 2015 | 296 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2014 | 709 | 0.030 |
Why?
|
| Graft vs Tumor Effect | 1 | 2011 | 139 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 4314 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2013 | 430 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 1217 | 0.020 |
Why?
|
| Infertility | 1 | 2013 | 123 | 0.020 |
Why?
|
| Comorbidity | 1 | 2017 | 2352 | 0.020 |
Why?
|
| Ultrasonography | 1 | 1997 | 1863 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 6009 | 0.020 |
Why?
|
| Data Collection | 1 | 2013 | 620 | 0.020 |
Why?
|
| Premedication | 1 | 2009 | 135 | 0.020 |
Why?
|
| HSP27 Heat-Shock Proteins | 1 | 2009 | 33 | 0.020 |
Why?
|
| Risk | 1 | 2013 | 1972 | 0.020 |
Why?
|
| Drug Therapy | 1 | 2009 | 205 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2015 | 3033 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 1742 | 0.020 |
Why?
|
| Liver Neoplasms | 1 | 2005 | 4557 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2013 | 1459 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2011 | 1487 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2018 | 4078 | 0.020 |
Why?
|
| Pain | 1 | 2015 | 1658 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2009 | 1313 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 2403 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2011 | 1688 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2009 | 1764 | 0.020 |
Why?
|
| Tandem Repeat Sequences | 1 | 2006 | 201 | 0.020 |
Why?
|
| Gene Expression | 1 | 2013 | 3570 | 0.020 |
Why?
|
| Palliative Care | 1 | 1996 | 2037 | 0.020 |
Why?
|
| Ribavirin | 1 | 2005 | 178 | 0.010 |
Why?
|
| STAT3 Transcription Factor | 1 | 2009 | 1121 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2011 | 2173 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2020 | 10331 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2005 | 15694 | 0.010 |
Why?
|
| Interferon-alpha | 1 | 2005 | 889 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2013 | 5687 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 3639 | 0.010 |
Why?
|
| Pregnancy | 1 | 2012 | 7573 | 0.010 |
Why?
|
| Immunotherapy | 1 | 2011 | 3341 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 1995 | 7789 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2006 | 7548 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2011 | 7551 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2005 | 7702 | 0.010 |
Why?
|
| Cisplatin | 1 | 1993 | 2432 | 0.000 |
Why?
|